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FMV 1953 uropathogenic Escherichia coli isolate was extremely resistant to amoxicillin, co-amoxiclav, 
ticarcillin, mecillinam, cefoxitime, cefixime, cefuroxime, cefotaxime, ceftazidime, ceftriaxone and 
aztreoname. From the resistance patterns observed we deduce the phenotype as producing a TEM-1 β 
-lactamase, a hyperproduced Amp-C β-lactamase and an OXA-3 β-lactamase or a PBP-2 mutation 
isolate. 
 





Since the description of the first TEM-derived β- 
lactamases conferring resistance to clavulanate, a 
number of these enzymes have emerged in various parts 
of the world, as profiled by Jacoby and Bush (1997). 
There is little information available on resistance to β-
lactam– β -lactamase inhibitor combinations in members 
of the family Enterobacteriaceae in Portugal (Caniça et 
al., 2000; Féria et al., 2002). 
In this study, we describe the susceptibility of 
uropathogenic E. coli isolated from animals in Portugal to 
β -lactams and β lactamase-inhibitor combinations and 
the relationship between the predominant mechanisms of 
resistance and the production of β-lactamases. 
 
 
MATERIALS AND METHODS 
 
Forty-five E. coli isolates from canines (28), felines (6), suines (7), 
equines (1) and humans (3) with significant bacteriuria and clinical 
symptoms of urinary tract infection (UTI) were collected from urine 
specimens at the Veterinary Medical School. Isolates were 
identified with the API 20E system (bioMérieux, Marcy l’Etoile, 
France). E. coli ATCC 25922, E. coli R111 (TEM-1), E. coli Sal 
(IRT-1), E. coli Guer (IRT-2), E. coli P37 (IRT-14) were used as a 
reference control for microdilution  testing.  The  minimum  inhibitory  
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concentration (MIC) microdilution assay was based on standard 
procedures (Medeiros, 1997). An inoculum of 5 x 105 cfu/mL was 
used. Susceptibility patterns were interpreted according to the 
recommendations of the Antibiogram Committee of the American 
Society for Microbiology (1992). Antibiotic and β--lactamase-
inhibitor powders for MIC assays were provided by the following 
manufacturers: clavulanic acid and ticarcillin (GlaxoSmithKline, 
Oeiras, Portugal), mecillinam (Leo Pharmaceutical Products, 
Lisbon, Portugal), cefoxitime and cefixime (Lilly Farma, Oeiras, 
Portugal), ceftazidime (GlaxoWellcome, Oeiras, Portugal), 
ceftriaxone (Roche Pharmaceuticals, Amadora, Portugal), 
cefotaxime (Hoechst Marion Roussel, Sintra, Portugal), aztreonam 
(Bristol-Myers Squibb, Oeiras, Portugal). Amoxicillin was purchased 
from Sigma (Lisbon, Portugal). Clavulanate was used at a fixed 
concentration of 2 mg/L with serial two-fold dilutions of amoxicillin. 
 
 
RESULTS AND DISCUSSION 
 
The resistance patterns of 45 uropathogenic E. coli 
isolates to 10 β-lactams and one β--lactam– β--
lactamase-inhibitor combination are shown in Table 1. 
57.8% of these isolates were amoxicillin resistant, but 
only 28.6% were resistant to the combination of 
amoxicillin plus 2 mg/L clavulanate. We found that 53.3 
and 24.4% of isolates were resistant to ticarcillin and 
mecillinam, respectively. Ceftriaxone, cefotaxime and 
ceftazidime showed a very similar resistance pattern, with 
2.2, 2.2 and 4.5% of resistant isolates. Just 8.9% of 
isolates   were   resistant   to   cefoxitin    and    4.4%    to  




Table 1. In vitro activities of eleven antimicrobial agents against uropathogenic E. coli isolates (n = 45). 
 
                      
Cumulative percentages of isolates inhibited at a concentration of (mg/L) 
Antimicrobial
a
 <0.0015 0.0015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 4096 >4096 
AML       0 11 33 38 42 42 42 44 56 58 60 75 90 100  
AMC       0 21 35 48 65 73 73 79 83 85 90 92 100   
TIC     0 4 4 6 6 21 31 40 46 46 48 52 65 67 75 83 100 
MEC  0 6 21 44 48 52 58 73 81 90 92 94 96 98 100      
CAZ 2 4 11 15 26 49 83 87 94 94 96 96 96 96 96 100      
CRO 2 4 15 52 77 85 88 96 96 96 96 96 96 98 100       
CTX 2 8 10 29 67 77 77 79 88 90 94 96 98 100        
CXM     0 2 2 5 12 24 77 93 93 93 100       
CFM  0 5 5 7 19 66 89 89 89 89 91 93 96 96 100      
FOX   0 2 9 9 11 15 32 65 89 91 91 91 95 100      
ATM  0 2 12 25 65 82 84 84 86 92 97 100         
 
a
AML, amoxicillin; AMC, co-amoxiclav; TIC, ticarcillin; MEC, mecillinam; CXM, cefuroxime; CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; 
ATM, aztreonam; FOX, cefoxotime; CFM, cefixime. 
 
 
                 Table 2. MICs (mg/L) of the most resistant E. coli isolates (n = 7). 
 
MIC’s (mg/L) 
Isolate/control  AML AMC TIC MEC FOX CFM CXM CTX CAZ CRO ATM 
180 256 256 256 0.5 2 32 8 1 8 0.5 16 
199 128 128 16 0.125 128 64 128 8 2 0.5 0.25 
339 2048 64 2048 8 4 0.5 16 0.125 0.5 0.06 0.25 
1074 4096 64 >4096 1 8 1 8 0.125 0.5 0.06 1 
1187 4096 64 >4096 8 4 <0.03 8 2 0.5 0.03 0.25 
1953 4096 512 >4096 4096 256 256 128 128 256 128 64 
E939 4096 16 >4096 1024 4 0.5 8 0.125 0.03 0.125 0.25 
ATCC 4 4 4 0.06 1 0.5 4 0.25 0.25 0.03 0.25 
TEM-1 2048 128 >2048 4 ND ND ND 2 0.5 0.06 0.25 
IRT-1 128 4 128 <0.125 0.5 ND ND 0.015 0.25 0.015 0.25 
IRT-2 1024 512 1024 8 2 0.25 ND 0.015 0.25 0.03 0.25 
IRT-14 2048 1024 2048 0.25 4 ND  ND 0.015 0.25 0.06 0.06 
 
                   ND – not determined. 
 
 
cefuroxime. 9.1% of the isolates were resistant to 
cefixime. Only one of the isolates was resistant to 
aztreonam (Table 1). The FMV 1953 isolate showed 
resistance towards all tested antimicrobials (Table 2), 
suggesting the production of a TEM-1 β--lactamase, a 
hyper-expressed Amp-C β-lactamase and an OXA-3 β--
lactamase or a PBP-2 mutations. Although E. coli is 
recognized as an important pathogen in UTIs, little is 
known about antimicrobial resistance mechanisms in 
such isolates. Our results demonstrate that canine 
uropathogenic E. coli isolates have a high level of in vitro 
resistance to amoxicillin (57.8%), mecillinam (24.4%), 
ticarcillin (53.3%) and co-amoxiclav (28.6%), but that they 
are generally susceptible to other β--lactams. Similar data 
was found in other studies of uropathogenic E. coli in 
dogs in Portugal and the UK (Féria et al., 2000, 2002). 
We found an important pattern of resistance to 
amoxicillin and co-amoxiclav, which are first-line and 
overused drugs for UTI therapy in dogs in Portugal. The 
production of TEM-1, AmpC and OXA-3 enzymes in 
uropathogenic canine E. coli is of concern. This study 
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